{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"}],"units":"Participants"}],"description":"A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria:\n\n* fatal,\n* life threatening (places the participant at immediate risk of death),\n* required in-patient hospitalization or prolongation of existing hospitalization,\n* resulted in persistent or significant disability/incapacity,\n* congenital anomaly/birth defect, and/or\n* other medically important serious event.","groups":[{"description":"Ganitumab 20 mg/kg once every 4 weeks by intravenous infusion.","id":"OG000","title":"20050118: Ganitumab 20 mg/kg"},{"description":"Conatumumab 0.45 mg/kg every 2 weeks by intravenous infusion.","id":"OG001","title":"20050171: Conatumumab 0.45 mg/kg"},{"description":"Conatumumab 3 mg/kg every 3 weeks by intravenous infusion.","id":"OG002","title":"20060295: Conatumumab 3 mg/kg"},{"description":"Conatumumab 5 mg/kg once every 3 weeks by intravenous infusion.","id":"OG003","title":"20060340: Conatumumab 5 mg/kg"},{"description":"Conatumumab 2 mg/kg once every 2 weeks by intravenous infusion in addition to modified FOLFOX6 chemotherapy and bevacizumab 5 mg/kg once every 2 weeks.","id":"OG004","title":"20060464: Conatumumab 2 mg/kg + mFOLFOX6 + Bevacizumab"},{"description":"Conatumumab 10 mg/kg once every 2 weeks by intravenous infusion in addition to modified FOLFOX6 chemotherapy, with or without bevacizumab 5 mg/kg once every 2 weeks.","id":"OG005","title":"20060464: Conatumumab 10 mg/kg + mFOLFOX6 ± Bevacizumab"},{"description":"Conatumumab 15 mg/kg and ganitumab 18 mg/kg once every 3 weeks by intravenous infusion.","id":"OG006","title":"20070411: Conatumumab 15 mg/kg + Ganitumab 18 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received at least one dose of conatumumab or ganitumab.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug in the extension study to 30 days after last dose; median duration of treatment with conatumumab was 1190.5 days and 1163.0 days for ganitumab.","title":"Number of Participants With Serious Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}